Galapagos(US:GLPG) Globenewswireยท2025-07-23 20:03Core Insights - Galapagos NV has appointed Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer, effective August 4, 2025, to strengthen its leadership team [1][2][3] Group 1: Leadership Appointments - Sooin Kwon brings nearly 30 years of experience in life sciences, having previously served as a Partner at MTS Health Partners, where she led strategic and financing transactions [2][3] - Dan Grossman has over 20 years of experience in biopharmaceutical strategy and business development, previously working at Boston Consulting Group as Managing Director and Senior Partner [3][4] Group 2: Strategic Goals - The new executives are expected to play a critical role in advancing Galapagos' transformation, adding new pipeline assets through business development, and enhancing the company's impact on global health [2][3] - Kwon emphasized the company's strong balance sheet and partnership with Gilead, positioning Galapagos to execute transactions that will build a portfolio of innovative medicines [3] Group 3: Company Overview - Galapagos is a biotechnology company focused on transforming patient outcomes through innovative science and technology, with operations in Europe, the U.S., and Asia [5] - The company aims to address high unmet medical needs and is committed to delivering results for patients, employees, and shareholders [5]